Trial Outcomes & Findings for Weight Loss and Exercise for Communities With Arthritis in North Carolina (NCT NCT02577549)

NCT ID: NCT02577549

Last Updated: 2023-06-27

Results Overview

To determine whether a pragmatic, community-based, 18-month diet-induced weight-loss and exercise intervention implemented in three North Carolina counties with diverse residential (from urban to rural) and socioeconomic composition significantly decreases knee pain \[as measured by the Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) pain subscale\] in overweight and obese adults with knee Osteoarthritis (OA) compared to an attention-control group - test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4) - Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations - The WOMAC measures five items for pain (score range 0-20). Measure Description: Range, 0 to 20 (0, no pain; 2 to 8, mild; \>8 to 14, moderate; and \>14 to 20, severe); between-group MCID = 1.6, calculated as half the SD.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

823 participants

Primary outcome timeframe

18 months

Results posted on

2023-06-27

Participant Flow

We used overlapping recruitment strategies. A combination of mailings, local newspaper ads, and direct targeting through electronic health records were used. We also had strong ties with local aging service networks and access to senior centers, senior high-rise residential sites, churches, and a large database of older adults who signed consent to be contacted about participating in future clinical trials.

Participant milestones

Participant milestones
Measure
Diet & Exercise
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight.
Attention Control
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month.
Overall Study
STARTED
414
409
Overall Study
COMPLETED
336
332
Overall Study
NOT COMPLETED
78
77

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Weight Loss and Exercise for Communities With Arthritis in North Carolina

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Diet & Exercise
n=414 Participants
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight. Diet \& Exercise: Participants attended exercise and diet classes.
Attention Control
n=409 Participants
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month. Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
Total
n=823 Participants
Total of all reporting groups
Age, Continuous
64.5 years
STANDARD_DEVIATION 7.8 • n=5 Participants
64.7 years
STANDARD_DEVIATION 7.8 • n=7 Participants
64.6 years
STANDARD_DEVIATION 7.8 • n=5 Participants
Sex: Female, Male
Female
320 Participants
n=5 Participants
317 Participants
n=7 Participants
637 Participants
n=5 Participants
Sex: Female, Male
Male
94 Participants
n=5 Participants
92 Participants
n=7 Participants
186 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
7 Participants
n=5 Participants
3 Participants
n=7 Participants
10 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
407 Participants
n=5 Participants
401 Participants
n=7 Participants
808 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
5 Participants
n=7 Participants
5 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants
Race (NIH/OMB)
Asian
2 Participants
n=5 Participants
1 Participants
n=7 Participants
3 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
111 Participants
n=5 Participants
116 Participants
n=7 Participants
227 Participants
n=5 Participants
Race (NIH/OMB)
White
289 Participants
n=5 Participants
281 Participants
n=7 Participants
570 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
11 Participants
n=5 Participants
10 Participants
n=7 Participants
21 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Womac pain score
7.5 score on a scale
STANDARD_DEVIATION 3.2 • n=5 Participants
7.5 score on a scale
STANDARD_DEVIATION 3.3 • n=7 Participants
7.5 score on a scale
STANDARD_DEVIATION 3.2 • n=5 Participants

PRIMARY outcome

Timeframe: 18 months

Population: A total of 13 persons (7 in D\&E and 6 in attention control) did not complete this testing measure but completed other measures.

To determine whether a pragmatic, community-based, 18-month diet-induced weight-loss and exercise intervention implemented in three North Carolina counties with diverse residential (from urban to rural) and socioeconomic composition significantly decreases knee pain \[as measured by the Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) pain subscale\] in overweight and obese adults with knee Osteoarthritis (OA) compared to an attention-control group - test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4) - Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations - The WOMAC measures five items for pain (score range 0-20). Measure Description: Range, 0 to 20 (0, no pain; 2 to 8, mild; \>8 to 14, moderate; and \>14 to 20, severe); between-group MCID = 1.6, calculated as half the SD.

Outcome measures

Outcome measures
Measure
Diet & Exercise
n=329 Participants
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight. Diet \& Exercise: Participants attended exercise and diet classes.
Attention Control
n=316 Participants
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month. Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
Knee Pain
5.0 score on a scale
Interval 4.6 to 5.4
5.5 score on a scale
Interval 5.1 to 5.9

SECONDARY outcome

Timeframe: 18 months

Population: Not all persons completing the study completed this measure at follow up.

To determine whether a pragmatic, community-based, 18-month, diet-induced weight-loss and exercise intervention improves WOMAC self-reported function in overweight and obese adults with knee OA compared to an attention control group - test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4) - Higher scores on the WOMAC indicate more pain, stiffness, and functional limitations. The WOMAC function score is a total of seventeen items for function (total score range 0-68). Measure Description: Range, 0 to 68 (0, no difficulty; 68, extreme).

Outcome measures

Outcome measures
Measure
Diet & Exercise
n=325 Participants
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight. Diet \& Exercise: Participants attended exercise and diet classes.
Attention Control
n=311 Participants
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month. Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
Function
16.5 score on a scale
Interval 15.3 to 17.7
19.8 score on a scale
Interval 18.6 to 21.0

SECONDARY outcome

Timeframe: 18 months

Population: Not all persons completing the study completed this measure at follow up.

To determine whether a pragmatic, community-based, 18-month, diet-induced weight-loss and exercise intervention improves health-related quality of life as measured by the physical subscale of the SF-36 questionnaire in overweight and obese adults with knee OA compared to an attention control group - Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state - The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.

Outcome measures

Outcome measures
Measure
Diet & Exercise
n=321 Participants
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight. Diet \& Exercise: Participants attended exercise and diet classes.
Attention Control
n=306 Participants
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month. Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
Health Related Quality of Life (SF-36) Physical Subscale
41.4 score on a scale
Interval 40.2 to 42.6
37.6 score on a scale
Interval 36.3 to 38.8

SECONDARY outcome

Timeframe: 18 months

Population: Not all persons completing the study completed this measure at follow up.

To determine whether a pragmatic, community-based, 18-month, diet-induced weight-loss and exercise intervention improves 6-minute walk distance (an accepted measure of mobility) in overweight and obese adults with knee OA compared to an attention control group.

Outcome measures

Outcome measures
Measure
Diet & Exercise
n=247 Participants
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight. Diet \& Exercise: Participants attended exercise and diet classes.
Attention Control
n=219 Participants
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month. Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
Mobility (Six Minute Walk)
419 meters
Interval 411.0 to 428.0
376 meters
Interval 368.0 to 385.0

OTHER_PRE_SPECIFIED outcome

Timeframe: 18 months

Population: Currently only data for the primary outcome and some of the secondary outcomes have been analyzed and published. Additional analyses are being conducted. The cost effectiveness outcome measure will be available to report in the coming months.

To establish the cost-effectiveness of this pragmatic, community-based, multimodal diet-induced weight-loss and exercise program by conducting cost-effectiveness and budgetary impact analyses using data from the current trial in a validated computer-simulated model of knee OA.

Outcome measures

Outcome data not reported

Adverse Events

Diet & Exercise

Serious events: 67 serious events
Other events: 107 other events
Deaths: 0 deaths

Attention Control

Serious events: 96 serious events
Other events: 93 other events
Deaths: 3 deaths

Serious adverse events

Serious adverse events
Measure
Diet & Exercise
n=414 participants at risk
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight. Diet \& Exercise: Participants attended exercise and diet classes.
Attention Control
n=409 participants at risk
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month. Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
Injury, poisoning and procedural complications
Car Accident
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.73%
3/409 • Number of events 3 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Injury, poisoning and procedural complications
Fall
0.24%
1/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.49%
2/409 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Injury, poisoning and procedural complications
Surgery Complications
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.49%
2/409 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Injury, poisoning and procedural complications
Fracture
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Injury, poisoning and procedural complications
Burn
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Injury, poisoning and procedural complications
Ruptured Blood Vessel
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Gall Bladder Surgery
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.49%
2/409 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Bariatric Surgery
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.73%
3/409 • Number of events 3 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Hip Replacement
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.73%
3/409 • Number of events 3 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Cardiac Monitor
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Other Knee Surgery
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Knee replacement
4.1%
17/414 • Number of events 19 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
5.6%
23/409 • Number of events 23 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Hernia Surgery
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Knee Amputation
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Laminectomy
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Oophorectomy
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Throat Surgery
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Appendectomy
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Cardiac Ablation
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Hysterectomy
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Intestinal Blockage Surgery
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Neck Surgery
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Shoulder Replacement Surgery
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Nervous system disorders
Numbness/Tingling
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Nervous system disorders
Fainting/Dizziness
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Nervous system disorders
Vertigo
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Psychiatric disorders
Mood Alteration
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Metabolism and nutrition disorders
Hypoglycemia
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Metabolism and nutrition disorders
Low Blood Sodium
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Cardiac disorders
Atrial Fibrillation
0.97%
4/414 • Number of events 4 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.98%
4/409 • Number of events 5 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Cardiac disorders
Chest Pain
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.98%
4/409 • Number of events 4 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Cardiac disorders
Stroke
1.2%
5/414 • Number of events 5 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Cardiac disorders
Heart Attack
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.49%
2/409 • Number of events 3 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Cardiac disorders
TIA
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.49%
2/409 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Cardiac disorders
Congestive Heart Failure
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.49%
2/409 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Cardiac disorders
AV Heart Block
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Cardiac disorders
Blood Clot
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Cardiac disorders
Bradycardia & Hypertension
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Cardiac disorders
Pulmonary Embolism
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Gastrointestinal disorders
Bowel Obstruction
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Gastrointestinal disorders
Ulcer
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Gastrointestinal disorders
Diverticulitis
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Gastrointestinal disorders
Ketoacidotic Coma
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Renal and urinary disorders
UTI
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Renal and urinary disorders
Colovesical Fistulitis
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Renal and urinary disorders
Enlarged Prostate
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Renal and urinary disorders
Cyst
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Renal and urinary disorders
Impaired Kidney Function
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Blood and lymphatic system disorders
Cancer
1.7%
7/414 • Number of events 7 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
2.2%
9/409 • Number of events 9 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Blood and lymphatic system disorders
Tumor
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Blood and lymphatic system disorders
Elevated PSA
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
General disorders
Rapid Weight Loss
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
General disorders
Cyst
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Respiratory, thoracic and mediastinal disorders
Breathing Difficulty
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Respiratory, thoracic and mediastinal disorders
Respiratory Failure and Coronary Artery Disease
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Infections and infestations
Cellulitis
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.49%
2/409 • Number of events 3 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Infections and infestations
Septic Shock
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Infections and infestations
Pneumonia
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Infections and infestations
Streptococcal Sepsis
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.49%
2/409 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Infections and infestations
Finger Infection
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Infections and infestations
Intestinal Infection
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Infections and infestations
Urosepsis
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.

Other adverse events

Other adverse events
Measure
Diet & Exercise
n=414 participants at risk
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight. Diet \& Exercise: Participants attended exercise and diet classes.
Attention Control
n=409 participants at risk
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month. Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
Injury, poisoning and procedural complications
Fall
17.1%
71/414 • Number of events 85 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
9.0%
37/409 • Number of events 46 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
Surgical and medical procedures
Knee Injection
8.7%
36/414 • Number of events 44 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
13.7%
56/409 • Number of events 75 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.

Additional Information

Dr. Stephen Messier

Wake Forest University

Phone: 336-758-5849

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place